Everything below concerns Toll-like receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-05. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
=== Pre-digital era === During the pre-digital era, patients suffered from inefficient and faulty clinical systems, processes, and conditions. Many medical errors happened in the past due to undeveloped health technologies. Some examples of these medical errors included adverse drug events and alarm fatigue. When many alarms are repeatedly triggered or activated, especially for unimportant events, workers may become desensitized to the alarms. Healthcare professionals who have alarm fatigue may ignore an alarm believing it to be insignificant, which could lead to death and dangerous situations. With technological development, an intelligent program of integration and physiologic sense-making was developed and helped reduce the number of false alarms. Also, with greater investment in health technologies, fewer medical errors happened. Outdated paper records were replaced in many healthcare organizations by electronic health records (EHR), with adoption in the United States increasing rapidly from the late 2000s to near-universal use by the early 2020s. According to studies, this has brought many changes to healthcare. Drug administration has improved, healthcare providers can now access medical information easier, provide better treatments and faster results, and save more costs.
== Research and career == In the 1980s, Mojsov moved to the Massachusetts General Hospital (MGH) where she was made head of a peptide synthesis facility. She arrived at MGH shortly after Joel Habener had cloned proglucagon by studying anglerfish found in Boston Harbor. Mojsov worked on the identification of glucagon-like peptide-1 (GLP-1), a hormone generated by the gut that triggers the release of insulin. The amino acid sequence of GLP-1 was similar to a gastric inhibitory peptide, an incretin. To try to identify whether a specific fragment of GLP-1 was an incretin, Mojsov synthesized an incretin-antibody and developed ways to track its presence. Specifically, Mojsov identified that a stretch of 31 amino acids in the GLP-1 was an incretin. Together with Gordon Weir at the Joslin Diabetes Center in Boston and Habener, Mojsov showed that physiologic concentration of 5 × 10−11 of lab-synthesized GLP-1 could trigger insulin. All other reports at that time were for much higher concentrations thus not meeting Cretuzfeld's requirement that an incretin "must stimulate insulin secretion in a glucose-dependent manner at physiological levels". In the 1990s, Mojsov returned to New York City, where she went back to Rockefeller University and the laboratory of Ralph M. Steinman (2011 Nobel Prize in Physiology or Medicine). In 1992, the group at Massachusetts General Hospital (MGH) using GLP-1 synthesized by Mojsov tested the GLP-1 in humans. Drugs that emulate the action of GLP-1 have been developed into treatments for obesity and diabetes by Novo Nordisk and Eli Lilly.
Redness of the sclera is typically caused by eye irritation causing blood vessels to expand, such as in conjunctivitis ("pink eye"). Episcleritis is a generally benign condition of the episclera causing eye redness. Scleritis is a serious inflammatory disease of the sclera causing redness of the sclera often progressing to purple. Yellowing or a light green color of the sclera is a visual symptom of jaundice. In cases of osteogenesis imperfecta, the sclera may appear to have a blue tint, more pronounced than the slight blue tint seen in children. The blue tint is caused by the showing of the underlying uveal tract (choroid and retinal pigment epithelium). In those with Ehlers–Danlos syndrome, the sclera may be tinted blue due to the lack of proper connective tissue. In very rare but severe cases of kidney failure and liver failure, the sclera may turn black. Early reports of white sclera in chimpanzees have been reported as possibly pathological and considered anomalies. Though this assumption is a good starting point in creating a foundation for what we know about sclera in animals, sources have experienced challenges acquiring large sample sizes in order to come up with conclusive evidence to support these claims fully.
== Side effects == The safety profile of HMB in adult humans is based upon evidence from clinical trials in humans and animal studies. In humans, no adverse effects in young adults or older adults have been reported when HMB is taken in doses of 3 grams per day for up to a year. Studies on young adults taking 6 grams of HMB per day for up to 2 months have also reported no adverse effects. Studies with supplemental HMB on young, growing rats and livestock have reported no adverse effects based upon clinical chemistry or observable characteristics; for humans younger than 18, there is limited data on the safety of supplemental HMB. The human equivalent dose of HMB for the no-observed-adverse-effect level (NOAEL) that was identified in a rat model is approximately 0.4 g/kg of body weight per day. Two animal studies have examined the effects of HMB supplementation in pregnant pigs on the offspring and reported no adverse effects on the fetus. No clinical testing with supplemental HMB has been conducted on pregnant women, and pregnant and lactating women are advised not to take HMB by Metabolic Technologies, Inc., the company that grants licenses to include HMB in dietary supplements, due to a lack of safety studies.
Signaling compounds called mitogens (specifically EGF in this case) arrive at the cell membrane, and bind to the extracellular domain of the HER family of receptors. Those bound proteins then link (dimerize), activating the receptor. HER2 sends a signal from its intracellular domain, activating several different biochemical pathways. These include the PI3K/Akt pathway and the MAPK pathway. Signals on these pathways promote cell proliferation and the growth of blood vessels to nourish the tumor (angiogenesis). ERBB2 is the preferred dimerization partner for the other family members and ERBB2 heterodimers signaling is stronger and longer acting compared to heterodimers between other ERBB members. It has been reported that Trastuzumab induces the formation of complementarity-determining regions (CDRs) leading to surface redistribution of ERBB2 and EGFR in CDRs and that the ERBB2-dependent MAPK phosphorylation and EGFR/ERBB1 expression are both required for CDR formation. CDR formation requires activation of both the protein regulator of actin polymerization N-WASP, mediated by ERK1/2, and of the actin-depolymerizing protein cofilin, mediated by EGFR/ERBB1. Furthermore, this latter event may be inhibited by the negative cell motility regulator p140Cap, as we found that p140Cap overexpression led to cofilin deactivation and inhibition of CDR formation. Normal cell division—mitosis—has checkpoints that keep cell division under control. Some of the proteins that control this cycle are called cdk2 (CDKs).
Sources: en.wikipedia.org
During HLF, koji-infused soybeans are exposed to air so that hydrolytic enzymes of the mold can continuously break down macronutrients within the soybean. Ample water, usually about 2 to 2.5 times the weight of the feed, is required to support sufficient microbial growth. High salt concentration (17–20%) is required to selectively inhibit microbial activity. HLF is generally carried out at 15–30 °C (59–86 °F), and requires a long ageing period, usually from 90 to 180 days. In the aging period, constant stirring of moromi (a mash/mixture of wheat (optionally), salt, soy beans, water, and fermenting yeast) is required for distributing nutrients, as well as flavoring compounds evenly. In some cases, moromi is exposed to direct sunlight to facilitate the decomposition of macronutrients. Due to the high salinity of HLF moromi, only anaerobic halophiles can survive in the medium. Also, the 15–30 °C (59–86 °F) temperature range allows only the growth of mesophiles. Similar to the fermentation of pickles, the primary lactic acid fermentation of sugars by halophiles reduces the pH of moromi down to acidic range. Low pH further limits the growth of undesirable microbes, but favors the growth of fermentative yeast which contributes to secondary fermentation that generates various flavoring compounds and odorants.
Administratively, Le Havre is a commune in the Normandy region in the west of the department of Seine-Maritime. The urban area of Le Havre corresponds roughly to the territory of the Agglomeration community of Le Havre (CODAH) which includes 17 communes and 250,000 people. It occupies the south-western tip of the natural region of Pays de Caux where it is the largest city. Le Havre is sandwiched between the coast of the Channel from south-west to north-west and the estuary of the Seine to the south.
=== Post-translational modifications and cofactors === Phosphorylation of the N-terminus not only prevents MDM2 binding but also facilitates the recruitment of cofactors. Pin1 enhances conformational changes in p53, while p300 and PCAF acetylate the C-terminus, exposing the DNA-binding domain and enhancing transcriptional activation. Conversely, deacetylases such as Sirt1 and Sirt7 remove these modifications, suppressing apoptosis and promoting cell survival. Some oncogenes can also activate p53 indirectly by inhibiting MDM2.
The Carpians, Goths and other neighbouring tribes made regular raids against Dacia from the 210s. The Romans could not resist, and Emperor Aurelian ordered the evacuation of the province Dacia Trajana in the 270s. Scholars supporting the continuity theory are convinced that most Latin-speaking commoners stayed behind when the army and civil administration was withdrawn. The Romans did not abandon their fortresses along the northern banks of the Lower Danube for decades, and Dobruja (known as Scythia Minor) remained an integral part of the Roman Empire until the early 7th century.
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.